Price RangeIf no approval or bankrupt most likely ZERO.
LET'S face it Theralase currently does not make a profit and has taken on debt. The timeline to get approved is not infinite, as other solutions will come to market.
However, the cancer treatment and the potential anti-microbial benefits of Ruthenium based compounds have a chance to succeed and come to market.
NMIBC treatment might be worth $1B, $2B, $4B or fully valued $8B depending on what stage TLT gets to before striking a deal. The cash burn would suggest that a deal sooner than later is in order. So, I would guess $2B might be more likely than $8B. Unless, there is a bidding war after BTD approval.
Present market cap is only $38M so you just have to do the math.
1,000/38 = 26 times current price.
2,000/38 = 52 times current price
4,000/38 = 104 times current price
8,000/38 = 208 times current price